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We present a case of myocardial infarction in a 19 year old female with cystic fibrosis who had a heart and lung
transplant performed at the age of four years old. She presented atypically with a one day history of severe,
intermittent, central, sharp chest pain, radiating to her back and down her left arm. A coronary angiogram showed
proximal stenosis of the left anterior descending artery and right coronary artery. She was treated with
percutaneous coronary intervention, involving drug eluting stents to the left anterior descending artery (LAD) and
the right coronary artery (RCA). In this study we discuss the pathophysiology, investigations and treatment of
cardiac transplant vasculopathy. Although complete reversal of LAD and RCA stenosis was achieved, routine follow-
up with coronary angiography and careful control of cardiac risk factors will be important to identify and reduce
future restenosis and adverse cardiac events.
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Heart and lung transplantation in children with cystic fi-
brosis (CF) and end-stage lung disease are now rarely
performed, with bilateral sequential lung transplantation
(BSLT) being the preferred procedure [1]. Although rare,
myocardial infarction (MI) in the perioperative period
following BSLT has been reported in patients with CF
[2-4]. However, to our knowledge there are no reports of
a MI occurring years after a heart and lung transplant-
ation in a patient with CF. We present a case of MI in a
19 year old female with CF who had a heart and lung
transplant performed at the age of four years old.Case presentation
A 19 year old female with CF who had a heart and lung
transplantation in 1997 presented to the Emergency De-
partment (ED) with a one day history of severe, intermit-
tent, central, sharp chest pain, radiating to her back and
down her left arm. This was associated with intermittent
paraesthesia, pallor and coldness in her left hand. The
chest pain was worse on deep inspiration but was not
positional or exacerbated by movement. Over the* Correspondence: jameseaden@doctors.org.uk
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distribution, and reproduction in any mediumprevious four weeks she had been having a productive
cough with a reduced exercise tolerance but no chest
pain.
On examination there was no swelling, pallor or ery-
thema of her left arm/hand and no chest wall tender-
ness. She was well perfused with a regular pulse and a
stable blood pressure. No murmur or added heart sound
was present and vesicular breath sounds were heard on
auscultation. A chest radiograph showed no acute
changes and an initial electrocardiogram (ECG) taken in
the ED showed a sinus tachycardia with no ST or T
wave changes. Initial blood tests were normal apart from
an elevated white cell count (13.64 × 109/L), creatinine
(138 μmol/L) and urea (12.8 μmol/L).
The patient was admitted from the ED to the CF ward
where she had a repeat ECG and a troponin I blood test
after being assessed by a junior doctor. The repeat ECG
showed sinus tachycardia with T wave inversion in leads
I, aVL, V2-V4, but no ST changes or Q waves. The
troponin I level (taken approximately 30 hours after the
onset of chest pain) was 10,801. A computed tomog-
raphy pulmonary angiogram (CTPA) the following day
showed no pulmonary embolus (PE) and no vascular
abnormalities. A coronary multi-slice computed tomog-
raphy (MSCT) was not performed as it is not used as anCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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versity Hospital.
Later that day the patient was reviewed by a cardiology
registrar who performed a bedside echocardiogram. This
demonstrated moderate left ventricular impairment due
to extensive apical akinesis and anterior/antero-septal
hypokinesis with an ejection fraction of 42%. No valvular
dysfunction was identified. That evening the patient re-
ceived percutaneous coronary intervention (PCI) which
illustrated a 95% proximal stenosis of the left anterior
descending artery (LAD), normal left circumflex artery
(LCx) and 80-95% proximal stenosis of the right coron-
ary artery (RCA) (Figure 1). Drug eluting stents (DES)
were inserted into the LAD and RCA and a complete re-
versal of the stenosis was achieved. The time between
the onset of chest pain and PCI (pain-to-needle time)
was approximately 60 hours. This delay in treatment
was due to the atypical nature of the chest pain as well
as late presentation to the ED. The patient was started
on aspirin, bisoprolol, ramipril, lansoprazole and 12
months of ticagrelor and was discharged from hospital
five days later.Discussion
Cardiac transplant vasculopathy (CTV) is a rapidly pro-
gressive form of atherosclerosis involving thickening ofFigure 1 Angiogram images. 95% proximal stenosis of LAD (A),
80-95% proximal stenosis of RCA (B), post-stenting of LAD (C), post-
stenting of RCA (D).the intima, leading to stenosis of coronary artery grafts
and subsequent myocardial ischaemia [5]. It is generally
a diffuse process that occurs early after transplantation.
However, years after transplantation there can be focal
atherosclerotic stenosis, diffuse intimal thickening or a
combination of both [6]. CTV is a significant complica-
tion as it is the leading cause of death in patients with a
heart transplant [7].
The development of CTV is thought to be due to a
combination of an immune-mediated process and non-
immunologic risk factors resulting in endothelial injury
and subsequent fibroelastic proliferation of the intima
[6]. Risk factors for CTV can be separated into trad-
itional risk factors (hypertension, hyperlipidaemia and
diabetes mellitus) and transplant associated risk factors
(donor factors, cytomegalovirus (CMV), HLA mismatch
and number of rejection episodes) [8]. The patient in
this case study did not have diabetes mellitus or hyper-
tension. There was no family history of premature is-
chaemic heart disease. She was not obese, did not smoke
and there was no history of drug abuse. There were no
concerns regarding her adherence to medication. She
had been taking pravastatin for at least five years and in
May 2012 she had a total cholesterol level of 3.5 mmol/L
and a triglyceride level of 1.4 mmol/L. There was no evi-
dence of CMV infection, HLA mismatch or rejection and
the details of the donor are unknown.
The diagnosis of CTV is particularly challenging as it
rarely presents with typical angina, despite 10-30% of pa-
tients with heart transplants having partial reinnervation
[6]. However, as demonstrated in this case report, CTV
can present with atypical chest pain. Many patients with
CTV seek medical attention with symptoms of congestive
heart failure (e.g. reduced exercise tolerance, dyspnoea on
exertion and orthopnoea) and will subsequently have im-
paired systolic function [6]. Others may present with ven-
tricular arrhythmias or sudden cardiac death [9] and
therefore early diagnosis of CTV is important.
In many transplant centres, patients with heart trans-
plants receive annual coronary angiography. However,
due to the diffuse nature of CTV, angiography may
underestimate the severity of disease or miss it com-
pletely [8]. The patient in this case study had a coronary
angiogram in 2003 and 2005 which were both normal.
The gold standard investigation of CTV is intravascu-
lar ultrasound (IVUS) which has the ability to assess the
amount of intimal thickness and identify vessel wall
morphology [8]. A study by Mehra et al. [10] involving
74 patients with a heart transplant showed that despite
having a normal coronary angiogram, the presence of in-
timal thickness of more than 0.5 mm on IVUS was asso-
ciated with more adverse cardiovascular events (death,
MI and retransplantation) after approximately four years
follow-up. A similar study by Rickenbacher et al. [11]
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plantation) demonstrated a significantly increased four-
year overall mortality in patients with a mean intimal
thickness of more than 0.3 mm on IVUS compared to
those with a mean intimal thickness of 0.3 mm or less.
Using serial IVUS Tsutsui et al. [12] found that the ma-
jority of intimal thickening occurs within the first year
following heart transplantation.
A number of non-invasive radiological modalities (e.g.
dobutamine stress echocardiography (DSE), myocardial
perfusion imaging (MPI) and multislice computed tom-
ography (CT) coronary angiography) have also been uti-
lized to assist in the diagnosis of CTV, with variable
degrees of sensitivity and specificity [8]. A pilot study by
Usta et al. [13] involving 10 asymptomatic patients with
heart transplants showed that multi-slice spiral CT was
equal to coronary angiography in detecting CTV in
epimyocardial vessel segments. Multi-slice spiral CT was
also more cost-effective with fewer complications when
compared with coronary angiography, making it a useful
alternative. A study by Spes et al. [14] comparing DSE
with coronary angiography and IVUS in 109 patients
with heart transplants found that DSE had a sensitivity
of 72%. The authors suggested that DSE has a similar
prognostic value as IVUS and coronary angiography and
that a normal DSE can justify postponing more invasive
investigations [14].
The most effective treatment of CTV is prevention
and modification of risk factors using antihypertensive
agents (e.g. ACE inhibitors and calcium channel
blockers), statins (e.g. pravastatin) and strict diabetic
control. Coronary artery bypass grafting is rarely an op-
tion in CTV due to the diffuse nature of the disease
process and the limited availability of donor hearts
makes re-transplantation unlikely. In patients with heart
transplants presenting with chest pain (atypical or an-
gina) or features of congestive heart failure, if the ECG
or echocardiogram show ischaemic changes or wall mo-
tion abnormalities, acute coronary syndrome should be
suspected and patients should be treated accordingly
with antiplatelet agents and PCI [6].
A systematic review of six small, retrospective,
nonrandomised studies comparing the use of bare-metal
stents (BMS) with drug-eluting stents (DES) in the treat-
ment of CTV (328 lesions treated with BMS and 287 le-
sions treated with DES) showed that DES were
associated with a lower restenosis rate at 6–12 months,
but in only half of the six studies were the differences
statistically significant [15]. There was no difference in
major adverse cardiac events between DES and BMS,
but the studies were underpowered and there was con-
siderable variation among the six studies in terms of
length of follow-up, type of DES used and the reason for
PCI [15]. Less than 20% of the coronary angiogramswere performed for possible acute coronary syndromes
or stable angina with the main indication being to screen
for CTV [15].
A recent retrospective nonrandomised study involving
34 patients receiving a total of 46 stents (27 DES vs 19
BMS) is the first to suggest a clinical benefit (reduced
rates of nonfatal MI and cardiac death) with DES
compared to BMS in the treatment of CTV [16].
Randomised controlled trials are required to confirm the
superiority of DES over BES in the treatment of CTV es-
pecially in improving survival or reducing major adverse
cardiac events [17].
Maintenance immunosuppression following heart
transplantation usually consists of a triple therapy of
corticosteroids (usually prednisolone), a calcineurin in-
hibitor (CNI) (cyclosporine or tacrolimus) and an
antiproliferative agent [18]. Azathioprine was the first
antiproliferative agent used post heart transplantation;
however this has now largely been replaced by
mycophenolate mofetil or newer agents such as
sirolimus and everolimus. A study involving 273 heart
transplant recipients found mycophenolate mofetil to be
significantly superior to azathioprine at preventing CTV
after five years, when combined with either tacrolimus
or cyclosporine [19]. In a randomised, multicentre study
involving 634 heart transplant recipients, everolimus was
shown to have greater efficacy in reducing the severity
and incidence of CTV after one year compared to aza-
thioprine [20]. Sirolimus has also been shown to reduce
the progression of CTV either in combination with a
CNI [21] or as primary immunosuppression [22,23].
However, the efficacy of everolimus and sirolimus
against the progression of CTV in the long-term waits
to be seen.
Tacrolimus and cyclosporine have failed to demon-
strate prevention of CTV after heart transplantation and
there appears to be little difference between these CNIs
in terms of long-term development of CTV [24]. How-
ever, tacrolimus has been shown to be associated with a
lower incidence of hyperlipidaemia and hypertension
with no difference in hyperglycaemia, renal function or
incidence of infection when compared to cyclosporine
[25]. It has also been suggested that tacrolimus mono-
therapy in heart transplant recipients is safe and effica-
cious and is not associated with increased high-grade
rejection or CTV [26,27].
In terms of CTV prevention, the optimum mainten-
ance immunosupression regime is unclear and a long-
term randomised trial is required to determine this. The
maintenance immunosupression regime following heart
and lung transplantation for the patient in this case
consisted of tacrolimus and prednisolone without the
use of an antiproliferative agent. There was no change in
the maintenance immunosupression regime post MI.
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MI must be considered in young patients with CF and a
heart and lung transplant with atypical chest pain. Al-
though complete reversal of LAD and RCA stenosis was
achieved in this case with the use of PCI and DES, rou-
tine follow-up with coronary angiography and careful
control of cardiac risk factors will be important to iden-
tify and reduce future restenosis and adverse cardiac
events.
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